Severe acute respiratory syndrome coronavirus 2 nucleoprotein (SARS-CoV-2 N protein)

The Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) nucleoprotein is a critical structural component of the virus, responsible for packaging the viral RNA genome into a helical ribonucleoprotein (RNP) complex (UniProt P0DTC9). It consists of two conserved domains—the N-terminal RNA-binding domain and the C-terminal dimerization domain—linked by an intrinsically disordered region (PMID: 32835717). Beyond its structural role in virion assembly, the nucleoprotein is essential for viral RNA replication and transcription, and it actively suppresses host immune responses by antagonizing interferon production (PMID: 33087934). Due to its high expression levels during infection and its relative sequence stability compared to the spike protein, it is the primary target for rapid diagnostic antigen tests and a key marker in serological assays (NCBI). Therapeutically, the nucleoprotein is being investigated as a target for small-molecule inhibitors, such as Naproxen or experimental compounds like PJ34, that disrupt its ability to bind RNA or form dimers (PMID: 33351214). These interventions offer a potential strategy to treat COVID-19 that may be less susceptible to mutational escape than spike-targeted therapies.

Other names

Nucleocapsid proteinN proteinProtein NSARS-CoV-2 nucleocapsid proteinNCAP_SARS2

Inhibition of viral RNA binding to the nucleocapsid protein, disruption of protein dimerization, or interference with the formation of the ribonucleoprotein complex to prevent viral replication and assembly.